Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	TRAIL receptor activity	TNFRSF10B TNFRSF10A	1.36e-04	4	96	2	GO:0036463
GeneOntologyMolecularFunction	TRAIL binding	TNFRSF10B TNFRSF10A	2.27e-04	5	96	2	GO:0045569
GeneOntologyCellularComponent	mRNA cleavage and polyadenylation specificity factor complex	WDR33 ZC3H3 MARVELD3	2.19e-04	26	95	3	GO:0005847
GeneOntologyCellularComponent	mRNA cleavage factor complex	WDR33 ZC3H3 MARVELD3	3.73e-04	31	95	3	GO:0005849
Domain	TNFR_10	TNFRSF10B TNFRSF10A	1.49e-04	4	94	2	IPR020465
Domain	-	SAFB SLTM SAFB2	1.54e-04	21	94	3	1.10.720.30
Domain	SAP	SAFB SLTM SAFB2	1.77e-04	22	94	3	PF02037
Domain	SAP	SAFB SLTM SAFB2	2.03e-04	23	94	3	SM00513
Domain	SAP	SAFB SLTM SAFB2	2.62e-04	25	94	3	PS50800
Domain	SAP_dom	SAFB SLTM SAFB2	2.62e-04	25	94	3	IPR003034
Domain	SAM_1	SHANK1 PHC3 CASKIN1 CNKSR3	3.83e-04	68	94	4	PF00536
Domain	SAM	SHANK1 PHC3 CASKIN1 CNKSR3	1.02e-03	88	94	4	SM00454
Domain	SAM_DOMAIN	SHANK1 PHC3 CASKIN1 CNKSR3	1.35e-03	95	94	4	PS50105
Domain	SAM	SHANK1 PHC3 CASKIN1 CNKSR3	1.46e-03	97	94	4	IPR001660
Domain	-	SHANK1 PHC3 CASKIN1 CNKSR3	2.02e-03	106	94	4	1.10.150.50
Domain	PLAC	PAPLN ADAMTSL4	2.19e-03	14	94	2	PF08686
Domain	MAM_1	MAMDC4 ALK	2.87e-03	16	94	2	PS00740
Domain	SAM/pointed	SHANK1 PHC3 CASKIN1 CNKSR3	2.89e-03	117	94	4	IPR013761
Domain	bHLH_dom	CDC42BPG SIM2 MESP2 LYL1	2.98e-03	118	94	4	IPR011598
Domain	Prot_kinase_dom	TNK1 CDC42BPG SPEG PLK5 MAST4 MAP3K10 MARVELD3 ALK	3.25e-03	489	94	8	IPR000719
Domain	MAM	MAMDC4 ALK	3.64e-03	18	94	2	PF00629
Domain	MAM_dom	MAMDC4 ALK	3.64e-03	18	94	2	IPR000998
Domain	MAM_2	MAMDC4 ALK	3.64e-03	18	94	2	PS50060
Domain	RRM_1	RBM26 SAFB PABPN1 SLTM SAFB2	4.02e-03	208	94	5	PF00076
Domain	CONNEXINS_1	GJC2 GJD4	4.05e-03	19	94	2	PS00407
Domain	PLAC	PAPLN ADAMTSL4	4.05e-03	19	94	2	PS50900
Domain	PLAC	PAPLN ADAMTSL4	4.05e-03	19	94	2	IPR010909
Domain	CONNEXINS_2	GJC2 GJD4	4.49e-03	20	94	2	PS00408
Domain	Connexin	GJC2 GJD4	4.49e-03	20	94	2	IPR000500
Domain	Connexin_CCC	GJC2 GJD4	4.49e-03	20	94	2	IPR019570
Domain	Connexin_N	GJC2 GJD4	4.49e-03	20	94	2	IPR013092
Domain	Connexin	GJC2 GJD4	4.49e-03	20	94	2	PF00029
Domain	Connexin_CCC	GJC2 GJD4	4.49e-03	20	94	2	SM01089
Domain	Connexin_CS	GJC2 GJD4	4.49e-03	20	94	2	IPR017990
Domain	CNX	GJC2 GJD4	4.49e-03	20	94	2	SM00037
Domain	RRM	RBM26 SAFB PABPN1 SLTM SAFB2	4.81e-03	217	94	5	SM00360
Domain	TNFR_c6	TNFRSF10B TNFRSF10A	5.42e-03	22	94	2	PF00020
Domain	PDZ	SHANK1 SHROOM2 MAST4 CNKSR3	5.62e-03	141	94	4	PF00595
Domain	RRM_dom	RBM26 SAFB PABPN1 SLTM SAFB2	5.80e-03	227	94	5	IPR000504
Domain	Ank	SHANK1 NFKBIZ CASKIN1 NFKBIL1 PPP1R16A	5.91e-03	228	94	5	PF00023
Domain	ADAM_spacer1	PAPLN ADAMTSL4	5.92e-03	23	94	2	IPR010294
Domain	ADAM_spacer1	PAPLN ADAMTSL4	5.92e-03	23	94	2	PF05986
Domain	RRM	RBM26 SAFB PABPN1 SLTM SAFB2	6.13e-03	230	94	5	PS50102
Domain	PDZ	SHANK1 SHROOM2 MAST4 CNKSR3	6.65e-03	148	94	4	SM00228
Domain	-	SHANK1 SHROOM2 MAST4 CNKSR3	6.97e-03	150	94	4	2.30.42.10
Domain	PDZ	SHANK1 SHROOM2 MAST4 CNKSR3	7.13e-03	151	94	4	PS50106
Domain	PDZ	SHANK1 SHROOM2 MAST4 CNKSR3	7.30e-03	152	94	4	IPR001478
Domain	TNFR	TNFRSF10B TNFRSF10A	7.53e-03	26	94	2	SM00208
Domain	-	RBM26 SAFB PABPN1 SLTM SAFB2	7.82e-03	244	94	5	3.30.70.330
Domain	DEATH	TNFRSF10B TNFRSF10A	8.11e-03	27	94	2	SM00005
Domain	-	SHANK1 NFKBIZ CASKIN1 NFKBIL1 PPP1R16A	8.35e-03	248	94	5	1.25.40.20
Domain	ANK	SHANK1 NFKBIZ CASKIN1 NFKBIL1 PPP1R16A	8.77e-03	251	94	5	SM00248
Domain	ANK_REPEAT	SHANK1 NFKBIZ CASKIN1 NFKBIL1 PPP1R16A	9.06e-03	253	94	5	PS50088
Domain	Ankyrin_rpt-contain_dom	SHANK1 NFKBIZ CASKIN1 NFKBIL1 PPP1R16A	9.20e-03	254	94	5	IPR020683
Domain	ANK_REP_REGION	SHANK1 NFKBIZ CASKIN1 NFKBIL1 PPP1R16A	9.20e-03	254	94	5	PS50297
Domain	TNFR_NGFR_1	TNFRSF10B TNFRSF10A	9.31e-03	29	94	2	PS00652
Domain	TNFR_NGFR_2	TNFRSF10B TNFRSF10A	9.31e-03	29	94	2	PS50050
Domain	SH3_2	SHANK1 CASKIN1 MAP3K10	9.35e-03	86	94	3	IPR011511
Domain	SH3_2	SHANK1 CASKIN1 MAP3K10	9.35e-03	86	94	3	PF07653
Domain	Nucleotide-bd_a/b_plait	RBM26 SAFB PABPN1 SLTM SAFB2	9.80e-03	258	94	5	IPR012677
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	SHANK1 FLNA APC2 RBM26 TRIOBP PPHLN1 SPECC1 PABPN1 SAFB2 VPS51 GPSM1 ADAMTSL4	7.84e-08	560	100	12	21653829
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SEMA6B ABCC3 FLNA SPOUT1 PCNX3 SPEG MUS81 FGFRL1 PAPLN HDAC7 INF2 CASKIN1 TXNRD3 MARVELD3 PPP1R16A	6.28e-07	1105	100	15	35748872
Pubmed	Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1.	FLNA RBM26 BUD23 KLF16 SAFB PABPN1 SLTM SAFB2 BSN FHL1 TSR3	2.94e-06	653	100	11	33742100
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	SHANK1 CACNA1B FLNA IQSEC2 TRIOBP SHROOM2 NACAD AMER2 SAFB CASKIN1 MAP3K10 BSN FHL1 VPS51	4.85e-06	1139	100	14	36417873
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	CACNA1B SPEG GJC2 AMER2 CASKIN1 SAFB2 BSN	4.93e-06	231	100	7	16452087
Pubmed	Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	11862476
Pubmed	Expression quantitative trait loci for TNFRSF10 influence both HBV infection and hepatocellular carcinoma development.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	26297860
Pubmed	Gli3 regulation of myogenesis is necessary for ischemia-induced angiogenesis.	E2F1 GLI3	8.18e-06	2	100	2	24044950
Pubmed	TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	26138346
Pubmed	Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	21785270
Pubmed	Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?	SAFB SAFB2	8.18e-06	2	100	2	14587024
Pubmed	A conserved CCCH-type zinc finger protein regulates mRNA nuclear adenylation and export.	ZC3H3 PABPN1	8.18e-06	2	100	2	19364924
Pubmed	Hypoxia/reoxygenation up-regulates death receptor expression and enhances apoptosis in human biliary epithelial cells.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	19643115
Pubmed	TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	20430723
Pubmed	The role of TRAIL death receptors in the treatment of hematological malignancies.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	18203008
Pubmed	SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.	SAFB SAFB2	8.18e-06	2	100	2	19901029
Pubmed	TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	29278689
Pubmed	TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	16544055
Pubmed	Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	24212133
Pubmed	Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	21272366
Pubmed	Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	34198757
Pubmed	Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	16051735
Pubmed	Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	20714870
Pubmed	Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	23498957
Pubmed	TRAIL and immunity: more than a license to kill tumor cells.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	15608691
Pubmed	Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	16778114
Pubmed	No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p.	SAFB SAFB2	8.18e-06	2	100	2	19077293
Pubmed	Low SAFB levels are associated with worse outcome in breast cancer patients.	SAFB SAFB2	8.18e-06	2	100	2	19137425
Pubmed	Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	22824792
Pubmed	8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	23423784
Pubmed	Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	15356269
Pubmed	Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	23460812
Pubmed	TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	19434100
Pubmed	Secretory stressors induce intracellular death receptor accumulation to control apoptosis.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	28981087
Pubmed	[Associations of Crohn's disease with DR4 and DR5 gene polymorphisms].	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	26418999
Pubmed	Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	14576771
Pubmed	Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	19424623
Pubmed	CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	11464292
Pubmed	Unravelling the RNA-Binding Properties of SAFB Proteins in Breast Cancer Cells.	SAFB SAFB2	8.18e-06	2	100	2	26273616
Pubmed	Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	17666396
Pubmed	Scaffold attachment factor B2 (SAFB2)-null mice reveal non-redundant functions of SAFB2 compared with its paralog, SAFB1.	SAFB SAFB2	8.18e-06	2	100	2	26092125
Pubmed	Scaffold attachment factor B (SAFB)1 and SAFB2 cooperatively inhibit the intranuclear mobility and function of ERα.	SAFB SAFB2	8.18e-06	2	100	2	22566185
Pubmed	Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis.	TNFRSF10B TNFRSF10A	8.18e-06	2	100	2	23806100
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	SHANK1 ZNF219 IQSEC2 APC2 TRIOBP JAKMIP3 NCDN CASKIN1 CNKSR3 SAFB2 BSN KCNT1	2.13e-05	963	100	12	28671696
Pubmed	TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	20354842
Pubmed	The enzymatic activity of SR protein kinases 1 and 1a is negatively affected by interaction with scaffold attachment factors B1 and 2.	SAFB SAFB2	2.45e-05	3	100	2	19674106
Pubmed	A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	28108622
Pubmed	Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	22447040
Pubmed	Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	15480430
Pubmed	Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	12388693
Pubmed	[Effect of tumor necrosis factor-related apoptosis-inducing ligand on developing human oligodendrocytes in culture].	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	25845236
Pubmed	c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	19932172
Pubmed	Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	12218097
Pubmed	Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	21279373
Pubmed	Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	16226105
Pubmed	The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	25230899
Pubmed	Expression of tumor necrosis factor- alpha -related apoptosis-inducing ligand and its proapoptotic receptors is down-regulated during gastric infection with virulent cagA+/vacAs1+ Helicobacter pylori strains.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	15655781
Pubmed	Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	16529749
Pubmed	The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	19212626
Pubmed	FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	15334061
Pubmed	Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	14534720
Pubmed	An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	27750195
Pubmed	Death receptor 5 is activated by fucosylation in colon cancer cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	30589515
Pubmed	Plexin-B2 controls the timing of differentiation and the motility of cerebellar granule neurons.	E2F1 EN1	2.45e-05	3	100	2	34100719
Pubmed	Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	31183506
Pubmed	Activated Cdc42-associated kinase 1 (Ack1) is required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor recruitment to lipid rafts and induction of cell death.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	24085293
Pubmed	IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	15208670
Pubmed	Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	19305384
Pubmed	Characterization of two receptors for TRAIL.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	9373179
Pubmed	Mutational analysis of death receptor genes Fas, TRAILR1 and TRAILR2 in prostate carcinomas.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	20666744
Pubmed	[Mechanism of leukemia cell apoptosis induced by sodium butyrate activating TRAIL pathway].	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	19379558
Pubmed	A novel receptor for Apo2L/TRAIL contains a truncated death domain.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	9382840
Pubmed	Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	16319225
Pubmed	Anti-cancer effect of bee venom on colon cancer cell growth by activation of death receptors and inhibition of nuclear factor kappa B.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	26561202
Pubmed	Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	20673328
Pubmed	Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	21769428
Pubmed	The human ZC3H3 and RBM26/27 proteins are critical for PAXT-mediated nuclear RNA decay.	RBM26 ZC3H3	2.45e-05	3	100	2	31950173
Pubmed	TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	31114586
Pubmed	Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	22158615
Pubmed	Hypoxia-induced interaction of filamin with Drp1 causes mitochondrial hyperfission-associated myocardial senescence.	CACNA1B FLNA	2.45e-05	3	100	2	30425165
Pubmed	The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	15452120
Pubmed	Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	17983809
Pubmed	TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	9311998
Pubmed	H-Ras regulation of TRAIL death receptor mediated apoptosis.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	25026275
Pubmed	TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	9430228
Pubmed	Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	10549288
Pubmed	Comparative binding to DR4 and DR5 receptors of TRAIL and BNNTs/PAHE/mPEG-DSPE/TRAIL nanoparticles.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	28120533
Pubmed	TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	22695614
Pubmed	TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	19074831
Pubmed	Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	12920112
Pubmed	Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.	TNFRSF10B TNFRSF10A	2.45e-05	3	100	2	23284732
Pubmed	Cloning and sequencing of the mouse Gli2 gene: localization to the Dominant hemimelia critical region.	GLI3 EN1	4.89e-05	4	100	2	9027508
Pubmed	Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	22183068
Pubmed	DDIT3 and KAT2A Proteins Regulate TNFRSF10A and TNFRSF10B Expression in Endoplasmic Reticulum Stress-mediated Apoptosis in Human Lung Cancer Cells.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	25770212
Pubmed	Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	24551275
Pubmed	Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	31473246
Pubmed	Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	30423122
Pubmed	TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	19637313
Pubmed	SAFB1 interacts with and suppresses the transcriptional activity of p53.	SAFB SAFB2	4.89e-05	4	100	2	21130767
Pubmed	Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane.	TNFRSF10B TNFRSF10A	4.89e-05	4	100	2	18165900
Interaction	SAA1 interactions	WDR33 PPHLN1 SAFB SLTM SAFB2	6.42e-06	54	98	5	int:SAA1
Cytoband	19p13.3	SEMA6B APC2 PLK5 CFD KLF16 SAFB2 ONECUT3	9.52e-07	237	100	7	19p13.3
Cytoband	Ensembl 112 genes in cytogenetic band chr19p13	SEMA6B APC2 PLK5 CFD KLF16 SAFB USHBP1 SAFB2 ONECUT3 LYL1	9.98e-06	797	100	10	chr19p13
Cytoband	Ensembl 112 genes in cytogenetic band chr9q34	CACNA1B SPOUT1 MAMDC4 GPSM1 KCNT1	7.49e-04	325	100	5	chr9q34
Cytoband	9q34.3	MAMDC4 GPSM1 KCNT1	1.64e-03	106	100	3	9q34.3
Cytoband	17p13.1	BORCS6 TNK1 PIK3R6	2.23e-03	118	100	3	17p13.1
Cytoband	7p13	NACAD GLI3	3.30e-03	39	100	2	7p13
GeneFamily	ADAMTS like	PAPLN ADAMTSL4	2.48e-04	7	63	2	947
GeneFamily	Sterile alpha motif domain containing	SHANK1 PHC3 CASKIN1 CNKSR3	2.51e-04	88	63	4	760
GeneFamily	RNA binding motif containing	RBM26 SAFB PABPN1 SLTM SAFB2	8.74e-04	213	63	5	725
GeneFamily	CD molecules\|Killer cell immunoglobulin like receptors	KIR2DL1 KIR2DS5	1.76e-03	18	63	2	620
GeneFamily	PDZ domain containing	SHANK1 SHROOM2 MAST4 CNKSR3	1.95e-03	152	63	4	1220
GeneFamily	Gap junction proteins	GJC2 GJD4	2.64e-03	22	63	2	314
GeneFamily	CD molecules\|Tumor necrosis factor receptor superfamily\|Death inducing signaling complex	TNFRSF10B TNFRSF10A	4.57e-03	29	63	2	782
GeneFamily	Zinc fingers CCCH-type	RBM26 ZC3H3	6.60e-03	35	63	2	73
GeneFamily	Basic helix-loop-helix proteins	SIM2 MESP2 LYL1	6.68e-03	110	63	3	420
GeneFamily	Ankyrin repeat domain containing	SHANK1 NFKBIZ CASKIN1 PPP1R16A	1.01e-02	242	63	4	403
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	TNFRSF10B TNFRSF10A KIR2DL1 KIR2DS5 ALK	1.20e-02	394	63	5	471
Coexpression	GSE7852_LN_VS_FAT_TCONV_UP	STAG1 RBM26 MAMDC4 HDAC7 NCDN MAST4 CNKSR3	1.04e-05	200	98	7	M5747
ToppCell	Macrophages-Cryobiopsy_01\|World / lung cells shred on cell class, cell subclass, sample id	ABCC3 FLNA CFD INF2 NFKBIL1 ADAMTSL4	3.88e-06	189	98	6	c05b4b565c0ce56dbb45fc9503654a2ec1a7e1e9
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-E\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	GJC2 JAKMIP3 NACAD AMER2 INF2 AMOTL2	4.50e-06	194	98	6	cb0422e7607dbd77204428b7e2c70dfe14a6ca11
Drug	h EE	SUMF2 SIM2 SAFB ALK	6.92e-08	10	99	4	CID000446896
Drug	Epirizole [18694-40-1]; Down 200; 17uM; PC3; HT_HG-U133A	ZNF219 SPOUT1 TNFRSF10B PTPN18 ZC3H3 HDAC7 SIRT3 FGD1	2.38e-06	197	99	8	1803_DN
Drug	Rifabutin [72559-06-9]; Down 200; 4.8uM; PC3; HT_HG-U133A	STAG1 SIM2 HDAC7 SIRT3 PHC3 SAFB LYL1	1.54e-05	183	99	7	4527_DN
Drug	Halcinonide [3093-35-4]; Up 200; 8.8uM; PC3; HT_HG-U133A	TRIOBP E2F1 SHROOM2 PTPN18 STOML1 EN1 ALK	2.25e-05	194	99	7	7379_UP
Drug	Ursolic acid [77-52-1]; Down 200; 8.8uM; PC3; HT_HG-U133A	SPEG HDAC7 SAFB LMAN1 GLI3 FGD1 FHL1	2.48e-05	197	99	7	2067_DN
Drug	Naproxen [22204-53-1]; Down 200; 17.4uM; PC3; HT_HG-U133A	FLNA HDAC7 CFD SAFB INF2 GLI3 FHL1	2.48e-05	197	99	7	1828_DN
Drug	Ivermectin [70288-86-7]; Up 200; 4.6uM; PC3; HT_HG-U133A	ABCC3 TNFRSF10B PTPN18 PHC3 LMAN1 SAFB2 LYL1	2.48e-05	197	99	7	2051_UP
Drug	STOCK1N-35874; Down 200; 14uM; PC3; HT_HG-U133A	ABCC3 SHROOM2 SIRT3 INF2 GLI3 FGD1 FHL1	2.48e-05	197	99	7	6561_DN
Drug	Dapsone [80-08-0]; Down 200; 16.2uM; MCF7; HT_HG-U133A	TNK1 ABCC3 PTPN18 CFD MAST4 BRPF1 FGD1	2.48e-05	197	99	7	1705_DN
Drug	Clemastine fumarate [14976-57-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A	TRIOBP E2F1 TNFRSF10B MAST4 LMAN1 STOML1 SAFB2	2.56e-05	198	99	7	7443_DN
Drug	Myosmine [532-12-7]; Down 200; 27.4uM; PC3; HT_HG-U133A	ABCC3 ZNF219 WDR33 TNFRSF10B PTPN18 MAST4 SAFB2	2.56e-05	198	99	7	4293_DN
Drug	Zoxazolamine [61-80-3]; Up 200; 23.8uM; MCF7; HT_HG-U133A	BORCS6 SEMA6B APC2 HDAC7 LMAN1 BSN FHL1	2.56e-05	198	99	7	5390_UP
Drug	2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A	BORCS6 ABCC3 GALR3 IQSEC2 GLI3 FGD1 AMOTL2	2.65e-05	199	99	7	5219_UP
Drug	Oxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; PC3; HT_HG-U133A	TNK1 E2F1 PTPN18 HDAC7 SIRT3 SAFB2 HCFC2	2.65e-05	199	99	7	6350_DN
Drug	Ricinine [524-40-3]; Down 200; 24.4uM; MCF7; HT_HG-U133A	TNK1 ABCC3 E2F1 TNFRSF10B PTPN18 MAST4 FHL1	2.73e-05	200	99	7	6206_DN
Drug	exemestane	TRIOBP SIM2 SAFB SAFB2	3.64e-05	43	99	4	CID000060198
Disease	FG syndrome	FLNA FGD1	6.26e-05	4	96	2	cv:C0220769
Disease	Urogenital Abnormalities	APC2 FGD1	2.18e-04	7	96	2	C0042063
Disease	Malignant neoplasm of breast	FLNA APC2 E2F1 PPHLN1 OCA2 JAKMIP3 SHROOM2 MAMDC4 HDAC7 ALK ZNF646	7.39e-04	1074	96	11	C0006142
Disease	angina pectoris	PCNX3 SIRT3 STOML1 FHL1	7.55e-04	125	96	4	EFO_0003913
Disease	head and neck squamous cell carcinoma (is_implicated_in)	TNFRSF10B TNFRSF10A	1.07e-03	15	96	2	DOID:5520 (is_implicated_in)
Disease	PR interval	SUMF2 PCNX3 PPHLN1 GJD4 CNKSR3 HCFC2 LINC02915	1.18e-03	495	96	7	EFO_0004462
Disease	Colorectal Carcinoma	SHANK1 ABCC3 IRS4 APC2 NCDN GJD4 AMER2 GLI3	2.08e-03	702	96	8	C0009402
Disease	osteoarthritis (biomarker_via_orthology)	TNFRSF10B TNFRSF10A	2.11e-03	21	96	2	DOID:8398 (biomarker_via_orthology)
Disease	fumarate measurement	CNKSR3 PPP1R16A	2.11e-03	21	96	2	EFO_0010480

Protein segments in the cluster

Peptide	Gene	Start	Entry
AHAEDARGTLPGRVP	PTPN18	401	Q99952
RRGRHAPPGELDPVA	USHBP1	11	Q8N6Y0
LRDRAGAALEGPGPH	MAMDC4	86	Q6UXC1
QAGTRPHAGDRDPRG	AMOTL2	121	Q9Y2J4
MASRGRRPEHGGPPE	BUD23	1	O43709
RGEDAAGHRRAEPGP	AMER2	296	Q8N7J2
AGHRRAEPGPGEVRT	AMER2	301	Q8N7J2
HPAPERAGGVGLVRS	C8orf82	156	Q6P1X6
RGGPLRGPASHLGRE	ADAMTSL4	121	Q6UY14
AIRAGGHGPDRVRPL	SPECC1	11	Q5M775
QPAGHRRPAGGIRES	C22orf31	131	O95567
DTIRGHPGPSRGGRQ	FLG	2136	P20930
GPEGGRRHHRRGSPE	CACNA1B	911	Q00975
ARHRGGPRAGPREAE	CACNA1B	956	Q00975
RGRGVPGHAVVDHRP	RBM26	876	Q5T8P6
RRLPRGAGGADPSHS	OCA2	36	Q04671
SSDGEGQGRPVPRRH	ABCC3	911	O15438
TRHGGEPDLRPEGRR	CDC42BPG	836	Q6DT37
LVHVGPANGRPGARD	CDC42BPG	1446	Q6DT37
PPRGRILGGREAEAH	CFD	21	P00746
GTPPREARPGRHGHS	CASKIN1	736	Q8WXD9
LSPPARPHGRREDVG	MAP3K10	721	Q02779
RPHGRREDVGPGLGL	MAP3K10	726	Q02779
DAPGHGVRRASDPVR	GLI3	996	P10071
SGAVVHRGRPGPEGA	KLF16	21	Q9BXK1
TGPVPRARHGHRAVA	HCFC2	16	Q9Y5Z7
SRGGARAERQPVEPH	NFKBIZ	86	Q9BYH8
AVAGTPRGPRHLIAG	NCDN	161	Q9UBB6
PRGPRHLIAGGTVSA	NCDN	166	Q9UBB6
TPGPTGQHDGRRRIQ	GJC2	191	Q5T442
QEGPDAERRPREGSH	GPSM1	456	Q86YR5
LPRSHRVAGRGPAEA	FAM86JP	16	Q05BU3
AAPERLGRGVHDTDP	MESP2	231	Q0VG99
LGRERGGREAGPAHP	IQSEC2	166	Q5JU85
RHTGGGDPAEHPLLR	KCNT1	1066	Q5JUK3
EPGRRAAKPHARDLG	BSN	3661	Q9UPA5
RGRPHREAAQDPRGS	GJD4	311	Q96KN9
AAGGPRKRRAPHGAE	PCNX3	461	Q9H6A9
GHRPPGTARDRSGDK	FGFRL1	416	Q8N441
TGRHPHGPATPRREG	PLK5	226	Q496M5
GSPRRELPHAAGAGD	JAKMIP3	261	Q5VZ66
DGVGGDPAVALPHRR	LMAN1	31	P49257
HRALARGPPARLGGE	HRES1	96	P13985
WPAGAAEPRHGRGRE	LRRC29	6	Q8WV35
PTRAGPREEHPRGAG	NFKBIL1	276	Q9UBC1
RTPGPSLHADAVRGG	PCDHGC3	736	Q9UN70
PGPGSGEASRILRVH	PLA2G10	26	O15496
RGQTAAGRDPVHPLG	EN1	146	Q05925
HRGRRPSGPDGAARE	PHC3	836	Q8NDX5
GLEDAVHSRGARPPA	INF2	1151	Q27J81
SREGEAHERRLPAGP	KIR2DS5	161	Q14953
PGRRRHLVPGAGGEA	PABPN1	21	Q86U42
PSANLRGRHPGGERT	FHL1	261	Q13642
ESPGGDLRHPGRVRR	GASK1A	106	Q9UFP1
PEPREGPVHGGEAAR	GALR3	351	O60755
AGHRRREEGPAPTGS	APC2	1316	O95996
AGSRRGAPGAEHEPS	BORCS6	91	Q96GS4
GNAAHPGSGATEPRR	CCDC107	36	Q8WV48
LAESSGPARGRGRHP	E2F1	101	Q01094
EGCDPSRVRVHGPGI	FLNA	1351	P21333
AGSGARHRPPRDRGT	LINC02875	231	Q86X59
VDEEGPEGRPRSRHG	EID2	116	Q8N6I1
PEGRPRSRHGNGGLA	EID2	121	Q8N6I1
DQGRTHDRPRDRPGD	MARVELD3	26	Q96A59
QVEEVGHRGGSSPPR	LYL1	41	P12980
PVHRVPDDGARRGSG	LYL1	226	P12980
PAEHRQGGGDFRRAP	MAST4	1626	O15021
HRELGHGQPEARGPA	HDAC7	426	Q8WUI4
SREGEAHERRLPAGP	KIR2DL1	161	P43626
RRSGPPHRGDESGYR	PPHLN1	71	Q8NEY8
EGIVVDRPTRPGHGS	SPOUT1	191	Q5T280
AAAQHRGLVAPGRPG	ONECUT3	31	O60422
AEIPEGAARGPHRAR	IRS4	676	O14654
GPGSGIRERLEHPVL	SUMF2	131	Q8NBJ7
PGLHRRTGRPSGDGE	PIK3R6	391	Q5UE93
GPPEAGERPDRRHVF	FGD1	876	P98174
EVVRPHNGRVGGSPV	PPP1R16A	406	Q96I34
REVSGHSVRGAPPGN	SLTM	906	Q9NWH9
PGGPEAATGALRLRH	SIM2	626	Q14190
SHCRGAPELPREGRG	SHROOM2	996	Q13796
RGSHGARGEPLDPAR	SIRT3	51	Q9NTG7
NQSRGERRGPPSDGH	TRIOBP	2051	Q9H2D6
PERHGGPERHGRDSR	SAFB	781	Q15424
SRGRHPEDAKRQPRG	SHANK1	501	Q9Y566
QRETGRDGPERHGPS	BRPF1	826	P55201
ISVRVPRGPAVEGGH	ALK	1461	Q9UM73
PFARPRGHGRKGEDA	CNKSR3	446	Q6P9H4
ITGKHGGRRPQRAEP	LINC02915	6	Q8N8G6
GPEGEAPERRRKAHG	VPS51	21	Q9UID3
PGDRHRGCHARPGTD	SEMA6B	856	Q9H3T3
GDRRVDAGHTDQPVP	ZC3H3	261	Q8IXZ2
AEPRGRHRRAGAPLE	SPEG	2136	Q15772
HPSARGDHRGERGDP	PAPLN	581	O95428
RGRVGHGVPDGIPDV	STOML1	336	Q9UBI4
RLEGHGRVHAPREGP	ZNF646	1746	O15015
AAEAHPPVGRGTGKR	STAG1	536	Q8WVM7
GHGGPPERHGRDSRD	SAFB2	806	Q14151
ASGARKRHGPGPREA	TNFRSF10B	11	O14763
QDGVARAPHGSRIPG	PYCARD-AS1	71	I3L0S3
QHGPSARARAGRAPG	TNFRSF10A	61	O00220
RGTPARGDQHPGSID	TNK1	456	Q13470
RSGHVRGARVLSPPG	TXNRD3	21	Q86VQ6
EESFRRGAPPRHEGR	WDR33	1101	Q9C0J8
REPGPGHEHFRDTPR	WDR33	1186	Q9C0J8
HRVRGGCVSPERGPT	ZNF777	596	Q9ULD5
QRHHREQRSGAGPGP	ZNF219	546	Q9P2Y4
AARGPGAEGGRPRHL	TSR3	6	Q9UJK0
HGPRSALGGAREVPD	NACAD	1091	O15069
GETRGGGHRPELLRE	MUS81	276	Q96NY9